Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 15;8(11):21428-34.
eCollection 2015.

Prostate cancer: a comparison of the diagnostic performance of transrectal ultrasound versus contrast enhanced transrectal ultrasound in different clinical characteristics

Hongli Li  1 , Jianguo Xia  1 , Shaowei Xie  1 , Yifen Guo  1 , Mei Xin  1 , Fenghua Li  1
Affiliations

Prostate cancer: a comparison of the diagnostic performance of transrectal ultrasound versus contrast enhanced transrectal ultrasound in different clinical characteristics

Hongli Li et al. Int J Clin Exp Med. .

Abstract

To determine whether contrast-enhanced transrectal ultrasound (CE-TRUS) is superior to transrectal ultrasound (TRUS) on diagnosis of prostate cancer, 317 patients were processed TRUS examination with or without SonoVue, then biopsy was performed. Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of two techniques were compared in multiple subgroups of PSA level, Digital rectal examination (DRE) and prostate volume on biopsy results. In PSA 4-10 ng/ml and DRE negative groups, CE-TRUS had greater sensitivity and accuracy compared with TRUS by patient (P = .004 and .003; .013 and .005 respectively) and greater sensitivity, accuracy, PPV and NPV by core. When prostate volume was 45-65 ml, CE-TRUS had greater specificity and accuracy by patient and all diagnostic performances were statistically significant by core. CE-TRUS is superior to TRUS on diagnosis of prostate cancer in a designed patient population with lower PSA level, DRE negative findings and modest prostate volume.

Keywords: Prostate cancer; biopsy; contrast agent; ultrasound.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Images acquired from a patient with clinical characteristics of 28.00 ng/ml PSA level, DRE positive of left gland, 84 years old and 33 ml prostate volume. Grey-scale image shows hypoechoic lesions in the left base (A1), mid (B1) and apex (C1) gland (arrows). Power Doppler image shows increased vessels in these areas (A2, B2, C2 respectively). Contrast enhanced ultrasound image shows rapidly enhancing lesions with greater contrast in these areas (A3, B3, C3 respectively) compared with corresponding left gland (arrows). Biopsy targeted to these suspicious areas reveals Gleason 7 prostate cancer. Moreover, contrast enhanced ultrasound image shows a low enhancement area in the right mid gland (arrow) compared with surrounding peripheral zone tissues. Biopsy targeted to this suspicious area reveals Gleason 7 prostate cancer.
See this image and copyright information in PMC

References

    1. Aus G, Abbou CC, Bolla M, Heidenreich A. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546–551. - PubMed
    1. Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. World J Urol. 2007;25:11–17. - PubMed
    1. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24:220–226. - PubMed
    1. Halpern EJ, McCue PA, Aksnes AK, Hagen EK, Frauscher F, Gomella LG. Contrast-enhanced US of the Prostate with Sonazoid: Comparison with Whole-Mount Prostatectomy Specimens in 12 Patients. Radiology. 2002;222:361–366. - PubMed
    1. Kuligowska E, Barish MA, Fenlon HM, Blake M. Predictors of Prostate Carcinoma: Accuracy of Grey-Scale and Color Doppler US and Serum Markers. Radiology. 2001;220:757–64. - PubMed

LinkOut - more resources